Science

Articles

• Vect-Horus demonstrates the high versatility of its peptide-vectors library for a targeted delivery of small molecules and protein cargos
  28 January 2019, by Jonathan NOWAK

  Identification and characterization of highly versatile peptide-vectors that bind non-competitively to the low-density lipoprotein receptor for in vivo targeting and delivery of small molecules and protein cargos.
  Marion David, Pascaline Lécorché, Maxime Masse, Aude Faucon, Karima Abouzid, Nicolas Gaudin, Karine Varini, Fanny Gassiot, Géraldine Ferracci, Guillaume Jacquot, Patrick Vlieghe, Michel Khrestchatisky
  http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0191052 (…)

• RadioMedix and Vect-Horus announce first dosing of Glioblastoma Multiforme and Pancreatic ductal adenocarcinoma patients with 68Ga-RMX-VH
  15 November 2022, by Elodie DORMES

  Houston, TX, USA and Marseille, France, Nov. 15, 2022 (GLOBE NEWSWIRE) — RadioMedix and Vect-Horus are pleased to announce that they have successfully dosed the first patients in an exploratory Investigational New Drug (eIND) application to evaluate 68Ga-RMX-VH for the diagnostic of Glioblastoma Multiforme (GBM) and Pancreatic ductal adenocarcinoma (PDAC). This radiotracer will serve as a companion diagnostic for future Targeted Alpha Therapy (TAT) for these cancers. 68Ga-RMX-VH is a (…)

• Meet Vect-Horus at 3rd Oligonucleotides for CNS Summit in Boston June 6-8th, 2023
  30 June 2023, by Elodie DORMES

  Meet with Michel KHRESTCHATISKY and Guillaume JACQUOT at the 3rd Oligonucleotides for CNS Summit 2023, dedicated to optimizing antisense and RNA chemistry for brain delivery, in Boston from June 6-8th, 2023.

• Vect-Horus participates to the event Radiopharmaceuticals & Imaging on March 14, 2023
  9 March 2023, by Elodie DORMES

  Cedric MALICET, Oncology Department Manager, will participate to the Radiopharmaceuticals & Imaging event next week ! You can book a meeting with him directly via the partnering system to discuss company developments on its theranostic agents.

• 3rd Annual RNAi-Based Therapeutics Summit from April 19th to 21th, 2022, in Boston
  12 April 2022, by Elodie DORMES

  Michel KHRESTCHATISKY, Scientific Counsel, will have a talk entitled “Development of Molecular Vectors for Targeted Delivery of RNAi” and Elodie DORMES, Sr BD Manager, will also be there and pleased to meet you in person during the summit.

• Vect-Horus Appoints Dr Jean-Manuel PEAN as Chief Scientific Officer
  3 April 2023, by Elodie DORMES

  Marseille, April 3rd, 2023 - VECT-HORUS, a biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced the appointment of Dr Jean-Manuel Péan as Chief Scientific Officer. In this role, he will lead the Company’s scientific programs and will be a member of the Management Committee of Vect-Horus.
  Alexandre Tokay, CEO and co-founder of VECT-HORUS said: "We are very pleased to have Jean-Manuel as our (…)

• Vect-Horus strengthens its scientific advisory board with the appointment of Dr. Julia ALTERMAN
  22 March 2022, by Elodie DORMES

  Vect-Horus extends its Scientific Advisory Board with the expertise of Dr. Julia Alterman on siRNA chemical modification for extra-hepatic delivery.

• Vect-Horus validates the potential of its peptide vectors to transport proteins or antibodies, across the blood-brain barrier via receptor mediated transport
  28 January 2019, by Jonathan NOWAK

  (Molino et al., 2017, The FASEB Journal)
  www.fasebj.org/content/early/2017/01/19/fj.201600827R.abstract

• TIDES Europe, Nov. 11-13, 2020 - 100% Virtual
  12 November 2020, by Elodie DORMES

  Dr Guillaume JACQUOT will share a presentation on “TfR-targeting VHH Nanobodies for Extra-hepatic Delivery of Oligonucleotides” a good opportunity for Vect-Horus to present its last results.
  A live Q&A session will also give the opportunity to ask questions on last trends and highlights in Oligonucleotide & Peptide Therapeutics field to expert panelists.
  TIDE is the Europe’s #1 forum for oligonucleotide and peptide leaders to build successful partnerships and accelerate new (…)

• Vect-Horus team will attend the 8AIS2020 symposium from Nov. 23-26, 2020
  12 November 2020, by Elodie DORMES

  Marion DAVID will be presenting a poster entitled “Development of versatile single domain antibody vectors that enhance brain deliver of antibodies by targeting the TfR transport system. ”
  Please use the partnering system to contact us and organize a 1&1 meeting : www.aiscongress.com